Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – US
Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – US
$599.00
An interview with a US key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine
Publisher: Biomedtracker
- Highlights
- Description
Highlights
- “I think the CDC has done a good campaign in terms of marketing to people to get their influenza vaccines, to debunk myths around influenza vaccination. There are patients who hardcore believe that you get the flu from the flu vaccine, and therefore refuse to get vaccinated, then there are patients who just refuse to accept any vaccine.”
- “I think people have become more accepting of influenza vaccination over the past 5–10 years, a lot of that I think stems from healthcare workers, and I can explain that, but for most of the US at this point, hospital and nursing homes mandate influenza vaccinations for employees who have patient contact, so that alone has really increased the rates of vaccination in healthcare workers over the past five years in particular.”
Drug Coverage
- Fluad
- Fluzone High dose
- FluMist Quadrivalent
- Flublok
- Flucelvax
- Universal flu vaccines
Overview
An interview with a US key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – UK 
Sign up to the